http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 08:01:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/60+Degrees+Pharma+signs+option+deal+with+Florida+State+for+tick+disease+compound/26744574.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) has entered into an exclusive option agreement with the Florida State University Research Foundation covering intellectual property related to the therapeutic development of castanospermine for tick-borne diseases, according to a press release.</p><p>Under the agreement, the Washington, D.C.-based company holds an exclusive option to negotiate a U.S. license for patented technology and know-how relating to the use of castanospermine in four disease areas: Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. The agreement also provides an evaluation period for the company to develop a commercialization strategy and supporting development plan.</p><p>Castanospermine is http://www.streetinsider.com/Corporate+News/60+Degrees+Pharma+signs+option+deal+with+Florida+State+for+tick+disease+compound/26744574.html Wed, 08 Jul 2026 08:01:46 -0400 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharma+signs+option+deal+with+Florida+State+for+tick+disease+compound/26744574.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) has entered into an exclusive option agreement with the Florida State University Research Foundation covering intellectual property related to the therapeutic development of castanospermine for tick-borne diseases, according to a press release.</p><p>Under the agreement, the Washington, D.C.-based company holds an exclusive option to negotiate a U.S. license for patented technology and know-how relating to the use of castanospermine in four disease areas: Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. The agreement also provides an evaluation period for the company to develop a commercialization strategy and supporting development plan.</p><p>Castanospermine is http://www.streetinsider.com/Corporate+News/60+Degrees+Pharma+signs+option+deal+with+Florida+State+for+tick+disease+compound/26744574.html Wed, 08 Jul 2026 08:01:46 -0400 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html <ul><li><strong>License </strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease</strong></li><li><strong>Agreement builds on Company&apos;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis</strong></li><li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development</strong><br/></li></ul> <p>WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Exclusive+Option+Agreement+with+Florida+State+University+to+Advance+Castanospermine+for+Tick-Borne+Diseases/26744567.html Wed, 08 Jul 2026 08:01:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/FDA/60+Degrees+Pharma+gets+safety+board+clearance+for+babesiosis+trial/26717175.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) announced that an independent Data Safety Monitoring Board has recommended continuation of its B-Free Phase 2 study after reviewing safety data from the first six patients through Day 30.</p> <p>The B-Free study is evaluating tafenoquine, sold under the brand name Arakoda, as a potential treatment for chronic babesiosis patients with severe persistent fatigue. The open-label trial is administering a loading dose of 200 mg per day for four days, followed by 200 mg weekly through Day 90.</p> <p>The study's primary endpoint is resolution of fatigue, measured by a patient-reported outcome tool at Day 90 compared to http://www.streetinsider.com/FDA/60+Degrees+Pharma+gets+safety+board+clearance+for+babesiosis+trial/26717175.html Wed, 01 Jul 2026 08:02:15 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/FDA/60+Degrees+Pharma+gets+safety+board+clearance+for+babesiosis+trial/26717175.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) announced that an independent Data Safety Monitoring Board has recommended continuation of its B-Free Phase 2 study after reviewing safety data from the first six patients through Day 30.</p> <p>The B-Free study is evaluating tafenoquine, sold under the brand name Arakoda, as a potential treatment for chronic babesiosis patients with severe persistent fatigue. The open-label trial is administering a loading dose of 200 mg per day for four days, followed by 200 mg weekly through Day 90.</p> <p>The study's primary endpoint is resolution of fatigue, measured by a patient-reported outcome tool at Day 90 compared to http://www.streetinsider.com/FDA/60+Degrees+Pharma+gets+safety+board+clearance+for+babesiosis+trial/26717175.html Wed, 01 Jul 2026 08:02:15 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/FDA/60+Degrees+Pharma+gets+safety+board+clearance+for+babesiosis+trial/26717175.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) announced that an independent Data Safety Monitoring Board has recommended continuation of its B-Free Phase 2 study after reviewing safety data from the first six patients through Day 30.</p> <p>The B-Free study is evaluating tafenoquine, sold under the brand name Arakoda, as a potential treatment for chronic babesiosis patients with severe persistent fatigue. The open-label trial is administering a loading dose of 200 mg per day for four days, followed by 200 mg weekly through Day 90.</p> <p>The study's primary endpoint is resolution of fatigue, measured by a patient-reported outcome tool at Day 90 compared to http://www.streetinsider.com/FDA/60+Degrees+Pharma+gets+safety+board+clearance+for+babesiosis+trial/26717175.html Wed, 01 Jul 2026 08:02:15 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html <p>WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DyCeYspBQJcGqydi410qq5xFuK4J6hdXjPtcUNK8-zt3_YroVWwpdXanggO2EkjOGbU4Rxnpq_gl7i3qDl-V0_xPUrTx9vl3m5wuTBMzgbofMn0jNFOHE0CT-YrlTkzCs6Ft6x57yMnK5ujZH0N2Tw==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=LzqTIcRHcvkCBah6rEqSmGvNj7v_H2eGunNS5I1Fv3IZ-0vLmxo6WyzByrmb9yFCaf95KUvXaB1pS8M0NuhN9dl_axP9tgFPFTU3ah89CeoitGCmNzmJNmZNHe4iVxI9" rel="nofollow" target="_blank">NCT06656351</a>), following a review of safety data from the first six patients from baseline through Day 30.</p> <p>The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of <strong>tafenoquine</strong> (loading dose of 200 mg per day for http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html Wed, 01 Jul 2026 08:02:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html <p>WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DyCeYspBQJcGqydi410qq5xFuK4J6hdXjPtcUNK8-zt3_YroVWwpdXanggO2EkjOGbU4Rxnpq_gl7i3qDl-V0_xPUrTx9vl3m5wuTBMzgbofMn0jNFOHE0CT-YrlTkzCs6Ft6x57yMnK5ujZH0N2Tw==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=LzqTIcRHcvkCBah6rEqSmGvNj7v_H2eGunNS5I1Fv3IZ-0vLmxo6WyzByrmb9yFCaf95KUvXaB1pS8M0NuhN9dl_axP9tgFPFTU3ah89CeoitGCmNzmJNmZNHe4iVxI9" rel="nofollow" target="_blank">NCT06656351</a>), following a review of safety data from the first six patients from baseline through Day 30.</p> <p>The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of <strong>tafenoquine</strong> (loading dose of 200 mg per day for http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html Wed, 01 Jul 2026 08:02:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html <p>WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DyCeYspBQJcGqydi410qq5xFuK4J6hdXjPtcUNK8-zt3_YroVWwpdXanggO2EkjOGbU4Rxnpq_gl7i3qDl-V0_xPUrTx9vl3m5wuTBMzgbofMn0jNFOHE0CT-YrlTkzCs6Ft6x57yMnK5ujZH0N2Tw==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=LzqTIcRHcvkCBah6rEqSmGvNj7v_H2eGunNS5I1Fv3IZ-0vLmxo6WyzByrmb9yFCaf95KUvXaB1pS8M0NuhN9dl_axP9tgFPFTU3ah89CeoitGCmNzmJNmZNHe4iVxI9" rel="nofollow" target="_blank">NCT06656351</a>), following a review of safety data from the first six patients from baseline through Day 30.</p> <p>The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of <strong>tafenoquine</strong> (loading dose of 200 mg per day for http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html Wed, 01 Jul 2026 08:02:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html <p>WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DyCeYspBQJcGqydi410qq5xFuK4J6hdXjPtcUNK8-zt3_YroVWwpdXanggO2EkjOGbU4Rxnpq_gl7i3qDl-V0_xPUrTx9vl3m5wuTBMzgbofMn0jNFOHE0CT-YrlTkzCs6Ft6x57yMnK5ujZH0N2Tw==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=LzqTIcRHcvkCBah6rEqSmGvNj7v_H2eGunNS5I1Fv3IZ-0vLmxo6WyzByrmb9yFCaf95KUvXaB1pS8M0NuhN9dl_axP9tgFPFTU3ah89CeoitGCmNzmJNmZNHe4iVxI9" rel="nofollow" target="_blank">NCT06656351</a>), following a review of safety data from the first six patients from baseline through Day 30.</p> <p>The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of <strong>tafenoquine</strong> (loading dose of 200 mg per day for http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html Wed, 01 Jul 2026 08:02:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html <p>WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DyCeYspBQJcGqydi410qq5xFuK4J6hdXjPtcUNK8-zt3_YroVWwpdXanggO2EkjOGbU4Rxnpq_gl7i3qDl-V0_xPUrTx9vl3m5wuTBMzgbofMn0jNFOHE0CT-YrlTkzCs6Ft6x57yMnK5ujZH0N2Tw==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=LzqTIcRHcvkCBah6rEqSmGvNj7v_H2eGunNS5I1Fv3IZ-0vLmxo6WyzByrmb9yFCaf95KUvXaB1pS8M0NuhN9dl_axP9tgFPFTU3ah89CeoitGCmNzmJNmZNHe4iVxI9" rel="nofollow" target="_blank">NCT06656351</a>), following a review of safety data from the first six patients from baseline through Day 30.</p> <p>The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of <strong>tafenoquine</strong> (loading dose of 200 mg per day for http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html Wed, 01 Jul 2026 08:02:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html <p>WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DyCeYspBQJcGqydi410qq5xFuK4J6hdXjPtcUNK8-zt3_YroVWwpdXanggO2EkjOGbU4Rxnpq_gl7i3qDl-V0_xPUrTx9vl3m5wuTBMzgbofMn0jNFOHE0CT-YrlTkzCs6Ft6x57yMnK5ujZH0N2Tw==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=LzqTIcRHcvkCBah6rEqSmGvNj7v_H2eGunNS5I1Fv3IZ-0vLmxo6WyzByrmb9yFCaf95KUvXaB1pS8M0NuhN9dl_axP9tgFPFTU3ah89CeoitGCmNzmJNmZNHe4iVxI9" rel="nofollow" target="_blank">NCT06656351</a>), following a review of safety data from the first six patients from baseline through Day 30.</p> <p>The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of <strong>tafenoquine</strong> (loading dose of 200 mg per day for http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Positive+Recommendation+from+Data+Safety+Monitoring+Board+for+B-FREE+Phase+2+Study+of+Tafenoquine+for+Treatment+of+Chronic+Babesiosis+Patients+with+Severe+Fatigue/26717172.html Wed, 01 Jul 2026 08:02:00 -0400 O.58280676 SXTP SXTPW